Randomized Phase II And Phase III Studies Of Individualized Treatment For Nasopharyngeal Carcinoma Based On Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nasopharyngeal Carcinoma
  • Age: Between 18 years - 90 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1. Patients must have biopsy proven diagnosis of cancer of the nasopharynx

    2. Patients must have detectable pretreatment plasma Epstein Bar Virus (EBV) DNA

    3. Patients must have stage II-IVB disease with no evidence of distant metastasis

You may not be eligible for this study if the following are true:

  • 1.  Prior invasive malignancy

    2.  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable

    3.  Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.